ALK‐rearranged CD30‐positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large‐cell lymphoma

HistopathologyEarly View Lesson of the Month ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma Giby V George, Giby V George Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorDanielle S Wallace, Danielle S Wallace Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorYing Wang, Ying Wang Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorJohn Carney, John Carney Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorMurad Elsadawi, Murad Elsadawi Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorW Richard Burack, W Richard Burack Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorAndrew G Evans, Andrew G Evans Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorPaul M Barr, Paul M Barr Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorMoises J Velez, Moises J Velez Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorSiba El Hussein, Corresponding Author Siba El Hussein [email protected] orcid.org/0000-0002-1338-7107 Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA Address for correspondence: S El Hussein, Department of Pathology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. e-mail: [email protected]Search for more papers by this author Giby V George, Giby V George Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorDanielle S Wallace, Danielle S Wallace Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorYing Wang, Ying Wang Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorJohn Carney, John Carney Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorMurad Elsadawi, Murad Elsadawi Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorW Richard Burack, W Richard Burack Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorAndrew G Evans, Andrew G Evans Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorPaul M Barr, Paul M Barr Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorMoises J Velez, Moises J Velez Department of Pathology, University of Rochester Medical Center, Rochester, NY, USASearch for more papers by this authorSiba El Hussein, Corresponding Author Siba El Hussein [email protected] orcid.org/0000-0002-1338-7107 Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA Address for correspondence: S El Hussein, Department of Pathology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. e-mail: [email protected]Search for more papers by this author First published: 30 November 2023 https://doi.org/10.1111/his.15105Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Conflict of interest None of the authors declare a conflict of interest. References 1Alaggio R, Amador C, Anagnostopoulos I et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36; 1720–1748. 10.1038/s41375-022-01620-2 PubMedWeb of Science®Google Scholar 2Yoshida A, Tsuta K, Nakamura H et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am. J. Surg. Pathol. 2011; 35; 1226–1234. 10.1097/PAS.0b013e3182233e06 PubMedWeb of Science®Google Scholar 3Tan Y, Lu X, Li Y et al. ALK-positive pulmonary adenocarcinoma with signet ring features (PASRF) and polygonal cell morphology simultaneously co-expressing TTF-1/p63/P40: a case report. Transl. Cancer Res. 2021; 10; 3864–3869. 10.21037/tcr-21-335 Web of Science®Google Scholar 4Chang ST, Chen SW, Chen BJ, Pan ST, Karube K, Chuang SS. Aberrant TTF-1 expression in peripheral T-cell lymphomas: a diagnostic pitfall. Int. J. Surg. Pathol. 2021; 29; 165–168. 10.1177/1066896920946835 CASWeb of Science®Google Scholar 5Kinney MC, Higgins RA, Medina EA. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch. Pathol. Lab. Med. 2011; 135; 19–43. 10.5858/2010-0507-RAR.1 PubMedWeb of Science®Google Scholar 6Sharman JP, Goldschmidt JH, Burke JM et al. Research MSHUO: CD30 expression in nonlymphomatous malignancies. J. Clin. Oncol. 2012; 15; 3069. ASCO annual meeting I, abstract 3069. 10.1200/jco.2012.30.15_suppl.3069 Google Scholar 7Cheng J, Zhu H, Choi JK. CD30 expression in pediatric neoplasms, study of 585 cases. Pediatr. Dev. Pathol. 2017; 20; 191–196. 10.1177/1093526616689185 PubMedWeb of Science®Google Scholar 8Feng Y, Dabir S, Minca EC, Lanigan C, Tubbs RR, Dowlati A. CD30 expression in non-small cell lung cancer with and without ALK gene rearrangement. J. Clin. Oncol. 2014; 32; ASCO annual meeting I, abstract e22146. 10.1200/jco.2014.32.15_suppl.e22146 Google Scholar 9Zhang X, Zhang S, Yang X et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol. Cancer 2010; 9; 188. 10.1186/1476-4598-9-188 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation